View Filing Data

Exercise Price

Number of
Units

Expiry Date

October 25, 2015

January 4, 2016

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Mar. 31, 2015	May 01, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	0001540159
Entity Filer Category	Accelerated Filer
Trading Symbol	SBOTF
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Period End Date	Mar. 31, 2015
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2015
Document Type	10-Q
Entity Common Stock, Shares Outstanding		79,546,650

Condensed Interim Consolidated Balance Sheets - USD ($)	Mar. 31, 2015	Sep. 30, 2014	Aug. 31, 2014
Current assets:
Cash and cash equivalents	$ 11,145,555	$ 13,769,953	$ 13,427,404
Accounts receivable	16,561	44,159	56,575
Short-term investments		448,632	458,098
Inventory	135,151	34,891
Prepaid expenses	145,016	125,840	128,593
Total current assets	11,442,283	14,423,475	14,070,670
Noncurrent assets:
Property, plant and equipment, net	368,432	388,340	387,392
Deposits	15,900	15,900	15,900
Total noncurrent assets	384,332	404,240	403,292
Total Assets	11,826,615	14,827,715	14,473,962
Current liabilities:
Accounts payable and accrued liabilities	413,941	585,047	526,626
Deferred revenue		86,667	15,000
Warrant liability, current portion	2,489,934	460	879,040
Total current liabilities	2,903,875	672,174	1,420,666
Long-term liabilities:
Warrant liability, less current portion		3,690,806	5,352,663
Total Liabilities	2,903,875	4,362,980	6,773,329
Commitments (Note 7)
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 79,546,650, 79,419,850 and 78,268,850 issued and outstanding at March 31, 2015, September 30, 2014 and August 31, 2014, respectively	37,940,641	37,883,877	36,240,838
Accumulated share-based compensation	5,244,026	5,073,144	5,079,985
Accumulated deficit	(34,261,927)	(32,492,286)	(33,620,190)
Total shareholders' equity	8,922,740	10,464,735	7,700,633
Total Liabilities and Shareholders' Equity	$ 11,826,615	$ 14,827,715	$ 14,473,962

Condensed Interim Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2015	Sep. 30, 2014	Aug. 31, 2014
Condensed Interim Consolidated Balance Sheets [Abstract]
Common shares, par value
Common shares, shares issued	79,546,650	79,419,850	78,268,850
Common shares, shares outstanding	79,546,650	79,419,850	78,268,850

Condensed Interim Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Contract services revenue	$ 45,000	$ 72,000	$ 105,000	$ 87,000
Product sales	142,627	42,371	295,288	58,456
Grant revenue				27,740
Revenues	187,627	114,371	400,288	173,196
Expenses:
Costs of contract services	59,760	27,258	76,457	37,664
Costs of production and aquaculture	250,236	147,982	410,640	294,913
Grant costs				27,740
Research and development	281,584	733,096	700,405	1,281,321
General and administration	785,681	646,670	1,727,834	1,667,800
Total Expenses	1,377,261	1,555,006	2,915,336	3,309,438
Other Income (Loss)
Foreign exchange gain (loss)	(307,546)	(182,321)	(468,658)	(198,829)
Increase (decrease) in fair value of warrant liability	1,061,776	185,607	1,201,332	(3,694,588)
Investment income	18,240	14,895	31,533	30,815
Other Income (Loss), Total	772,470	18,181	764,207	(3,862,602)
Loss Before Income Tax	(417,164)	(1,422,454)	(1,750,841)	(6,998,844)
Income tax expense	9,000	11,400	18,800	12,200
Net Loss	$ (426,164)	$ (1,433,854)	$ (1,769,641)	$ (7,011,044)
Loss per common share - basic	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.09)
Loss per common share - diluted	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.09)
Weighted average number of common shares outstanding, Basic	79,546,650	76,237,455	79,503,361	76,299,105
Weighted average number of common shares outstanding, Diluted	79,546,650	76,237,455	79,503,361	76,299,105

Condensed Interim Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash Flows Used In Operating Activities:
Net loss	$ (1,769,641)	$ (7,011,044)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	77,602	79,057
Share-based compensation	198,927	614,312
Foreign exchange (gain) loss	468,658	198,829
Change in fair value of warrant liability	(1,201,332)	3,694,588
Changes in working capital items:
Accounts receivable	26,867	87,643
Inventory	(100,260)
Prepaid expenses	(27,037)	(29,835)
Accounts payable and accrued liabilities	(168,575)	(193,727)
Deferred revenue	(86,667)
Net cash used in operating activities	(2,581,458)	(2,560,177)
Cash Flows Used In Investing Activities:
Acquisition of property, plant and equipment	(57,694)	(250,666)
Proceeds on maturities of short-term investments	424,813
Net cash provided by (used in) investing activities	367,119	(250,666)
Cash Flows From Financing Activities:
Proceeds from exercise of warrants and options	28,719	2,963,162
Net cash provided by financing activities	28,719	2,963,162
Effect of exchange rate changes on cash and cash equivalents	(438,778)	(205,712)
Net change in cash and cash equivalents	(2,624,398)	(53,393)
Cash and cash equivalents - beginning of period	13,769,953	15,478,038
Cash and cash equivalents - end of period	$ 11,145,555	$ 15,424,645

Nature of Operations

6 Months Ended

Mar. 31, 2015

Nature of Operations [Abstract]

Nature of Operations

Nature of Operations

Stellar Biotechnologies, Inc. (“the Company”) is organized under the laws of British Columbia, Canada. The Company's common shares are quoted on the U.S. OTCQB Marketplace Exchange under the trading symbol, SBOTF, and are listed on the TSX Venture Exchange as a Tier 2 issuer under the trading symbol, KLH.

On April 7, 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. On April 12, 2010, the Company completed a reverse merger transaction with Stellar Biotechnologies, Inc. a California corporation, which was founded in September 1999, and remains the Company's wholly-owned subsidiary and principal operating entity. The Company's executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada.

Nature of Operations

The Company's business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (“KLH”). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations in Europe, United States, and Asia.

Management Plans

For the six months ended March 31, 2015 and 2014, the Company reported net losses of approximately $1.8 million and $7.0 million, respectively. The most significant factor in the fluctuations in net income and losses relates to noncash changes in the fair value of warrant liability, which was a gain of $1.2 million and a loss of $3.7 million for the six months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, the Company had an accumulated deficit of approximately $34.3 million and working capital of approximately $8.5 million.

In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue, and product sales. In September 2013, the Company closed a private placement with gross proceeds of $12 million. Management believes these financial resources are adequate to support the Company's initiatives at the current level for at least 12 months. Management is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and the Company may seek additional financing alternatives, including nondilutive financing through grants, collaboration and licensing arrangements, and additional equity financing.

The accompanying condensed interim consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Functional Currency

The condensed interim consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company's functional currency.

Basis of Presentation

6 Months Ended

Mar. 31, 2015

Basis of Presentation [Abstract]

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. They do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. These condensed interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ended August 31, 2014.

The accompanying condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Stellar Biotechnologies, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the period presented have been included in the interim period. Operating results for the six months ended March 31, 2015 are not necessarily indicative of the results that may be expected for other interim periods or the year ending September 30, 2015. The condensed interim consolidated financial data at August 31, 2014 is derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended August 31, 2014, as filed on November 14, 2014 with the SEC.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.

Change in Fiscal Year End

On June 3, 2014, the Board of Directors of the Company approved a change in the Company's fiscal year end from August 31 to September 30 of each year. This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month transition period from September 1, 2014 to September 30, 2014. The unaudited results for the one month ended September 30, 2014 are included in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2014, as filed on February 9, 2015 with the SEC. The unaudited balance sheet at September 30, 2014 is included in these condensed interim consolidated financial statements for comparative purposes. The audited results for the one month ended September 30, 2014 will be included in the Company's Annual Report on Form 10-K for the fiscal year ending September 30, 2015, if not filed with the SEC prior thereto.

In addition, the results for the three months and six months ended March 31, 2015 are compared with the results of the three months and six months ended March 31, 2014, which have been recast on a calendar quarter basis due to the change in the Company's fiscal year end from August 31 to September 30.

Significant Accounting Policies

6 Months Ended

Mar. 31, 2015

Significant Accounting Policies [Abstract]

Significant Accounting Policies

3.	Significant Accounting Policies

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 creates a new topic in the ASC Topic 606 and establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers, to provide guidance on costs related to obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early application is not permitted. In April 2015, the FASB proposed a one year deferral to the new revenue recognition guidance. Management is in the process of assessing the impact of ASU 2014-09 on the Company's financial statements.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after December 15, 2016, with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's financial statements.

Inventory

6 Months Ended

Mar. 31, 2015

Inventory [Abstract]

Inventory

4.	Inventory

The Company records inventory for custom manufacturing of products for specific customers, including manufacturing under supply agreements. Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for custom manufacturing in process at the end of the period. There are no finished goods since once the custom manufacturing is complete, products are shipped to the customer and removed from inventory. There was no inventory for custom manufactured products at August 31, 2014. Inventory consisted of the following at March 31, 2015 and September 30, 2014:

	March 31,		September 30,
	2015		2014

Raw materials	$	-	$	10,480
Work in process		135,151		24,411

	$	135,151	$	34,891

Property, Plant and Equipment, net

6 Months Ended

Mar. 31, 2015

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment, net

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following:

	March 31,			September 30,			August 31,
	2015			2014			2014

Aquaculture system	$	58,923		$	58,923		$	58,923
Laboratory facilities		62,033			62,033			62,033
Computer and office equipment		77,678			77,697			77,697
Tools and equipment		644,965			635,766			622,289
Vehicles		10,997			10,997			10,997
Leasehold improvements		108,990			61,187			61,187
		963,586			906,603			893,126
Less: accumulated depreciation		(595,154	)		(518,263	)		(505,734	)

	$	368,432		$	388,340		$	387,392

Depreciation expense amounted to $77,602 and $64,771 for the six months ended March 31, 2015 and 2014, respectively.

Intangible Assets - Licensing Rights

6 Months Ended

Mar. 31, 2015

Intangible Assets - Licensing Rights [Abstract]

Intangible Assets - Licensing Rights

Intangible Assets - Licensing Rights

In December 2010, the Company entered into a research collaboration agreement with a customer. When the agreement terminated according to its terms in August 2011, the Company acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed in collaboration with the customer. The Company paid a $200,000 license fee for the licensing rights, which are jointly owned by the Company and the customer. The licensing rights do not have a fixed term or termination provisions. The licensing rights are amortized over the estimated useful life of seven years and are shown net of accumulated amortization and impairment losses. During the year ended August 31, 2014, the Company discontinued its use of these licensing rights and recorded impairment loss for the remaining value of licensing rights.

Amortization expense amounted to $14,286 for the six months ended March 31, 2014.

Commitments

6 Months Ended

Mar. 31, 2015

Commitments [Abstract]

Commitments

7.	Commitments

Operating leases

The Company leases three buildings and facilities used in its operations under sublease agreements with the Port Hueneme Surplus Property Authority. In September 2010, the Company exercised its option to extend these sublease agreements for an additional five-year term. The Company has an option to extend the lease for a second additional five-year term.

The Company also leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2014, the Company exercised its option to extend this lease for a two-year term.

Future minimum lease payments are as follows:

	March 31,
	2015
For The Year Ending September 30,
2015	$	79,000
2016		59,000
	$	138,000

Rent expense on these lease agreements amounted to approximately $91,000 and $90,000 for the six months ended March 31, 2015 and 2014, respectively.

Purchase obligations

The Company has commitments totaling approximately $70,000 at March 31, 2015 for signed agreements with contract manufacturing organizations and consultants. The Company also has agreements to pay time and materials to contractors, which are estimated at approximately $85,000 at March 31, 2015. All purchase obligations are expected to be fulfilled within the next 12 months.

Supply agreements

The Company has three commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer's field of use. One amended and restated supply agreement replaced two prior agreements that automatically renewed each year. The new agreement is effective through March 2020 and is renewable for one-year terms upon written request of the customer. One agreement is effective through October 2019 and is renewable for one-year terms upon written request of the customer. One agreement is effective through October 2017 and is renewable for one-year terms upon written request of the customer.

Licensing fees

In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”). The license agreement required an initial, non-refundable license fee of $25,000, which was paid in fiscal August 2013, and payment of an aggregate of $200,000 in delayed license fees, which were paid in fiscal August 2014. Beginning September 2014, the terms also require a license fee of $20,000 to be paid annually, creditable against royalties due, if any. Royalties are payable for a percentage of related net sales, if any. License fees are also payable for a percentage of related non-royalty sublicensing revenue, if any. No royalties are due or have been paid to date. The Company also reimbursed patent filing costs of approximately $30,000 and $22,000 in the six months ended March 31, 2015 and 2014, respectively, and will reimburse certain future patent filing, prosecution, and maintenance costs. License fees and patent cost reimbursements paid during the six months ended March 31, 2015 and 2014, have been accounted for as research and development expense in the accompanying condensed interim consolidated statements of operations.

The license agreement expires when the last valid patent claim licensed under the license agreement expires. Prior to that time, the license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 days after written notice from the licensor to cure the problem prior to termination of the license agreement. The Company can terminate the agreement with three months' prior written notice.

Upon execution of the license agreement, the Company issued 371,200 common shares and warrants to purchase up to 278,400 of the Company's common shares to the licensor. The warrants expired on January 23, 2015 and were not exercised.

The license agreement provides for the Company to pay up to an aggregate of $6,020,000 in milestone payments to the licensor upon achievement of various financing and development targets up to the first regulatory approval. Remaining contingent milestone payments to the licensor totaling $57,025,000 are related to achievement of sales targets. A financing milestone was met during the year ended August 31, 2014, and accordingly, the Company made a milestone payment of $100,000. No milestones were met during the six months ended March 31, 2015 and 2014, and there can be no assurance that any of the remaining milestones will be met in the future.

Retirement savings plan 401(k) contributions

The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages. All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately $33,000 and $27,000 for the six months ended March 31, 2015 and 2014, respectively.

Related party commitments

See Note 9.

Share Capital

6 Months Ended

Mar. 31, 2015

Share Capital [Abstract]

Share Capital

8. Share Capital

The Company had the following transactions in share capital:

	Six Months Ended
	March 31,		March 31,
	2015		2014

Number of common shares issued		126,800		6,475,820

Proceeds from exercise of warrants and broker units	$	938	$	2,587,014
Transfer to common shares on exercise of warrants and broker units		426		5,308,382
Proceeds from exercise of options		27,781		376,148
Transfer to common shares on exercise of options		27,619		341,594
Share-based compensation		198,927		614,312

Performance shares

There were 10,000,000 common shares allotted as performance shares to be issued to certain officers, directors and employees of the Company based on meeting milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products under a performance share plan. Share-based compensation was recorded over the estimated vesting period ending in August 2012.

At March 31, 2015, there are 3,838,383 performance shares reserved for issuance.

Black-Scholes option valuation model

The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and stock options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company's warrants, broker units and stock options.

Warrants

A summary of the Company's warrants activity is as follows:

	Number of Warrants			Weighted Average Exercise Price

Balance - September 30, 2014		10,545,312		$	1.01	CDN $

Exercised		(600	)		0.75	CDN $
Expired		(278,700	)		1.25	CDN $

Balance - March 31, 2015		10,266,012		$	1.15	CDN $

The weighted average contractual life remaining on the outstanding warrants at March 31, 2015 is 1.09 years.

The following table summarizes information about the outstanding warrants at March 31, 2015:

Exercise Price	Number of Warrants		Expiry Date

CDN$ 0.40		4,000,000	October 25, 2015
CDN$ 0.40		278,400	January 4, 2016
$ 1.35		4,701,902	September 9, 2016
$ 1.05		200,000	September 9, 2016	Broker warrants
$ 1.35		952,377	September 20, 2016
$ 1.05		133,333	September 20, 2016	Broker warrants

		10,266,012

Warrant liability

Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company's functional currency is the U.S. dollar. As a result of having exercise prices denominated in other than the Company's functional currency, these warrants meet the definition of derivatives and are therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants are exercised, the fair value of the recorded warrant liability on date of exercise is included in common shares along with the proceeds from the exercise. If these warrants expire, the related decrease in warrant liability is recognized in profit or loss, as part of the change in fair value of warrant liability. There is no cash flow impact as a result of this accounting treatment.

The fair value of the warrants is determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities is reclassified to equity.

The fair value of warrants exercised during the six months ended March 31, 2015 and 2014 was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:

	Six Months Ended
	March 31, 2015			March 31, 2014
Risk free interest rate		1.12	%		1.07	%
Expected life (years)		0.01			0.29
Expected share price volatility		97	%		106	%

There were no warrants granted during the six months ended March 31, 2015 and 2014.

Broker units

The Company granted broker units as finders' fees in conjunction with equity offerings in prior years. Broker units are fully vested when granted and allow the holders to purchase equity units. A unit consists of one common share and either one whole warrant or one half warrant to purchase common shares.

A summary of broker units activity is as follows:

	Number of Units			Weighted Average Exercise Price

Balance - September 30, 2014		467,200		$	0.25	CDN $

Exercised		(1,200	)		0.50	CDN $

Balance - March 31, 2015		466,000		$	0.25	CDN $

The weighted average contractual life remaining on the outstanding broker units is 0.60 years.

The following table summarizes information about the outstanding broker units at March 31, 2015:

Exercise Price	Number of Units		Expiry Date

CDN$ 0.25		400,000	October 25, 2015
CDN$ 0.25		66,000	January 4, 2016

		466,000

The outstanding broker units at March 31, 2015 include one warrant.

There were no broker units granted during the six months ended March 31, 2015 and 2014.

Options

The Company has a 2013 fixed stock option plan (“the Plan”) administered by the Board of Directors, who have the discretion to grant up to an aggregate of 10,000,000 options. The exercise price of an option is set at the closing price of the Company's common shares on the date of grant. Stock options granted to directors, officers, employees and consultants are subject to the following vesting schedule:

(a)

One-third of the shares subject to the option shall vest immediately;

(b)

One-third of the shares subject to the option shall vest 12 months from the date of grant; and

(c)

One-third of the shares subject to the option shall vest 18 months from the date of grant.

Stock options granted to investor relations consultants vest over a period of not less than 12 months with 25% of the shares subject to the option vesting on the date that is three months from the date of grant, and a further 25% vesting on each successive date that is three months from the date of the prior vesting.

Options have been granted under the Plan allowing the holders to purchase common shares of the Company as follows:

	Number of Options			Weighted Average Exercise Price

Balance - September 30, 2014		5,885,533		$	0.62	CDN $

Granted		102,500			1.52	CDN $
Exercised		(125,000	)		0.25	CDN $

Balance - March 31, 2015		5,863,033		$	0.67	CDN $

The weighted average contractual life remaining on the outstanding options is 3.70 years.

The following table summarizes information about the options under the Plan outstanding and exercisable at March 31, 2015:

Exercise Price	Number of Options		Exercisable at March 31, 2015		Expiry Date

CDN$ 0.28		1,645,000		1,645,000	April 9, 2017
CDN$ 0.25		55,000		55,000	May 17, 2017
CDN$ 0.28		20,000		20,000	June 28, 2017
CDN$ 0.28		70,000		70,000	July 13, 2017
CDN$ 0.64		70,000		70,000	October 25, 2017
CDN$ 1.00		60,000		60,000	February 10, 2018
CDN$ 0.65		848,600		848,600	August 8, 2018
CDN$ 0.50		5,000		5,000	September 26, 2018
CDN$ 1.87		100,000		66,667	November 7, 2018
CDN$ 0.40		70,000		70,000	December 22, 2018
CDN$ 0.42		853,600		853,600	April 13, 2019
CDN$ 0.29		90,000		90,000	June 18, 2019
CDN$ 0.37		150,000		150,000	August 9, 2019
CDN$ 0.37		150,000		150,000	August 16, 2019
CDN$ 0.25		8,333		8,333	October 23, 2019
CDN$ 0.25		215,000		215,000	December 19, 2019
CDN$ 0.58		560,000		560,000	May 14, 2020
CDN$ 0.58		100,000		100,000	May 23, 2020
$ 1.83		495,000		330,000	November 1, 2020
$ 1.84		100,000		66,667	November 15, 2020
CDN$ 0.94		95,000		31,667	June 27, 2021
CDN$ 1.52		102,500		34,167	November 12, 2021
		5,863,033		5,499,701

The estimated fair value of the stock options granted during the six months ended March 31, 2015 and 2014 was determined using a Black-Scholes option valuation model with the following weighted average assumptions.

	Six Months Ended
	March 31, 2015			March 31, 2014
Risk free interest rate		1.71	%		1.98	%
Expected life (years)		7.00			6.71
Expected share price volatility		116	%		120	%
Expected dividend yield		0	%		0	%

The weighted average fair value of stock options awarded during the six months ended March 31, 2015 and 2014 was CDN$1.34 and CDN$1.51, respectively.

As of March 31, 2015, the Company had approximately $80,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period of 1.25 years.

The intrinsic value of the options exercised during the six months ended March 31, 2015 and 2014 was CDN$1.15 and CDN$1.32, respectively. The intrinsic value of the vested options at March 31, 2015 was $0.63.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Related Party Disclosures

12 Months Ended

Aug. 31, 2014

Related Party Disclosures

9.	Related Party Disclosures

Royalty agreement

On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company's current operations utilize this invention. There was no royalty expense incurred during the six months ended March 31, 2015 and 2014.

Collaboration agreement

In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwan biopharmaceuticals manufacturer and a beneficial owner of over 5% of the Company's common shares. Under the terms of the agreement, the Company will be responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in the collaboration partner's potential manufacture of OBI-822 active immunotherapy. The Company is also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The collaboration partner is responsible for development objectives and product specifications. The agreement provides for the collaboration partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing, the collaboration also provides for the parties to negotiate a commercial supply agreement for Stellar KLH™ in the future. However, there can be no assurance that any such negotiations will lead to successful execution of any further agreements related to this collaboration.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

6 Months Ended

Mar. 31, 2015

Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

10. Supplemental Disclosure of Cash Flow and Non-Cash Transactions

Supplemental disclosure of cash flow information follows:

	Six Months Ended
	March 31,		March 31,
	2015		2014

Cash paid during the period for taxes	$	18,800	$	12,200

Supplemental disclosure of non-cash financing and investing activities follows:

	Six Months Ended
	March 31,		March 31,
	2015		2014

Transfer to common shares on exercise of warrants and broker units	$	426	$	5,308,382
Transfer to common shares on exercise of options		27,619		341,594
Shares subscribed transferred to common shares		-		77,736

Concentrations of Credit Risk

12 Months Ended

Aug. 31, 2014

Concentrations of Credit Risk [Abstract]

Concentrations of Credit Risk

11.

Concentrations of Credit Risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash, cash equivalents and accounts receivable. Management's assessment of the Company's credit risk for cash and cash equivalents is low as cash and cash equivalents are held in financial institutions believed to be credit worthy. The Company limits its exposure to credit loss by placing its cash with major financial institutions and invests only in short-term obligations.

Approximately 82% and 77% of the Company's product sales and contract services revenue during the six months ended March 31, 2015 and 2014, respectively, were from two customers. All of the grant revenue during the six months ended March 31, 2015 was received from the National Science Foundation.

Approximately 43% and 76% of the Company's accounts receivable at March 31, 2015 and August 31, 2014, respectively, were from one customer and approximately 81% of the Company's accounts receivable at September 30, 2014 was from two customers.

While the Company is exposed to credit losses due to the non-performance of its counterparties, the Company considers the risk of this remote. The Company estimates its maximum credit risk for accounts receivable at the amount recorded on the balance sheet.

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 creates a new topic in the ASC Topic 606 and establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers, to provide guidance on costs related to obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. Early application is not permitted. In April 2015, the FASB proposed a one year deferral to the new revenue recognition guidance. Management is in the process of assessing the impact of ASU 2014-09 on the Company's financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after December 15, 2016, with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company's financial statements.

Inventory (Tables)

6 Months Ended

Mar. 31, 2015

Inventory [Abstract]

Inventory

	March 31,		September 30,
	2015		2014

Raw materials	$	-	$	10,480
Work in process		135,151		24,411

	$	135,151	$	34,891

Property, Plant and Equipment, net (Tables)

6 Months Ended

Mar. 31, 2015

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment, net

	March 31,			September 30,			August 31,
	2015			2014			2014

Aquaculture system	$	58,923		$	58,923		$	58,923
Laboratory facilities		62,033			62,033			62,033
Computer and office equipment		77,678			77,697			77,697
Tools and equipment		644,965			635,766			622,289
Vehicles		10,997			10,997			10,997
Leasehold improvements		108,990			61,187			61,187
		963,586			906,603			893,126
Less: accumulated depreciation		(595,154	)		(518,263	)		(505,734	)

	$	368,432		$	388,340		$	387,392

Commitments (Tables)

6 Months Ended

Mar. 31, 2015

Commitments [Abstract]

Schedule of Future Minimum Lease Payments

Future minimum lease payments are as follows:

	March 31,
	2015
For The Year Ending September 30,
2015	$	79,000
2016		59,000
	$	138,000

Share Capital (Tables)

6 Months Ended

Mar. 31, 2015

Share Capital [Abstract]

Transactions In Share Capital

The Company had the following transactions in share capital:

	Six Months Ended
	March 31,		March 31,
	2015		2014

Number of common shares issued		126,800		6,475,820

Proceeds from exercise of warrants and broker units	$	938	$	2,587,014
Transfer to common shares on exercise of warrants and broker units		426		5,308,382
Proceeds from exercise of options		27,781		376,148
Transfer to common shares on exercise of options		27,619		341,594
Share-based compensation		198,927		614,312

Schedule of Warrant Activity

A summary of the Company's warrants activity is as follows:

	Number of Warrants			Weighted Average Exercise Price

Balance - September 30, 2014		10,545,312		$	1.01	CDN $

Exercised		(600	)		0.75	CDN $
Expired		(278,700	)		1.25	CDN $

Balance - March 31, 2015		10,266,012		$	1.15	CDN $

Summary of Warrants Outstanding

The following table summarizes information about the outstanding warrants at March 31, 2015:

Exercise Price	Number of Warrants		Expiry Date

CDN$0.40		4,000,000	October 25, 2015
CDN$0.40		278,400	January 4, 2016
$1.35		4,701,902	September 9, 2016
$1.05		200,000	September 9, 2016	Broker warrants
$1.35		952,377	September 20, 2016
$1.05		133,333	September 20, 2016	Broker warrants

		10,266,012

Schedule of Fair Value Of Warrants Exercised, Valuation Assumptions

	Six Months Ended
	March 31, 2015			March 31, 2014
Risk free interest rate		1.12	%		1.07	%
Expected life (years)		0.01			0.29
Expected share price volatility		97	%		106	%

Schedule of Broker Units Activity

A summary of broker units activity is as follows:

	Number of Units			Weighted Average Exercise Price

Balance - September 30, 2014		467,200		$	0.25	CDN $

Exercised		(1,200	)		0.50	CDN $

Balance - March 31, 2015		466,000		$	0.25	CDN $

Summary Of Broker Units Outstanding

The following table summarizes information about the outstanding broker units at March 31, 2015:

Schedule of Share-based Compensation Stock Options Activity

Options have been granted under the Plan allowing the holders to purchase common shares of the Company as follows:

	Number of Options			Weighted Average Exercise Price

Balance - September 30, 2014		5,885,533		$	0.62	CDN $

Granted		102,500			1.52	CDN $
Exercised		(125,000	)		0.25	CDN $

Balance - March 31, 2015		5,863,033		$	0.67	CDN $

Summary of Options Outstanding And Exercisable

The following table summarizes information about the options under the Plan outstanding and exercisable at March 31, 2015:

Exercise Price	Number of Options		Exercisable at March 31, 2015		Expiry Date

CDN$ 0.28		1,645,000		1,645,000	April 9, 2017
CDN$ 0.25		55,000		55,000	May 17, 2017
CDN$ 0.28		20,000		20,000	June 28, 2017
CDN$ 0.28		70,000		70,000	July 13, 2017
CDN$ 0.64		70,000		70,000	October 25, 2017
CDN$ 1.00		60,000		60,000	February 10, 2018
CDN$ 0.65		848,600		848,600	August 8, 2018
CDN$ 0.50		5,000		5,000	September 26, 2018
CDN$ 1.87		100,000		66,667	November 7, 2018
CDN$ 0.40		70,000		70,000	December 22, 2018
CDN$ 0.42		853,600		853,600	April 13, 2019
CDN$ 0.29		90,000		90,000	June 18, 2019
CDN$ 0.37		150,000		150,000	August 9, 2019
CDN$ 0.37		150,000		150,000	August 16, 2019
CDN$ 0.25		8,333		8,333	October 23, 2019
CDN$ 0.25		215,000		215,000	December 19, 2019
CDN$ 0.58		560,000		560,000	May 14, 2020
CDN$ 0.58		100,000		100,000	May 23, 2020
$ 1.83		495,000		330,000	November 1, 2020
$ 1.84		100,000		66,667	November 15, 2020
CDN$ 0.94		95,000		31,667	June 27, 2021
CDN$ 1.52		102,500		34,167	November 12, 2021
		5,863,033		5,499,701

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

	Six Months Ended
	March 31, 2015			March 31, 2014
Risk free interest rate		1.71	%		1.98	%
Expected life (years)		7.00			6.71
Expected share price volatility		116	%		120	%
Expected dividend yield		0	%		0	%

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Tables)

6 Months Ended

Mar. 31, 2015

Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]

Supplemental Disclosure of Cash Flow Information

Supplemental disclosure of cash flow information follows:

	Six Months Ended
	March 31,		March 31,
	2015		2014

Cash paid during the period for taxes	$	18,800	$	12,200

Supplemental Disclosure of Non-Cash Financing and Investing Activities

Supplemental disclosure of non-cash financing and investing activities follows:

	Six Months Ended
	March 31,		March 31,
	2015		2014

Transfer to common shares on exercise of warrants and broker units	$	426	$	5,308,382
Transfer to common shares on exercise of options		27,619		341,594
Shares subscribed transferred to common shares		-		77,736

Nature of Operations (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
Nature of Operations (Details) - USD ($)	Sep. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Aug. 31, 2014
Nature of Operations [Abstract]
Net loss		$ (426,164)	$ (1,433,854)	$ (1,769,641)	$ (7,011,044)
Accumulated deficit		(34,261,927)		(34,261,927)		$ (32,492,286)	$ (33,620,190)
Working capital		8,500,000		8,500,000
Changes in fair value of warrant liability		$ 1,061,776	$ 185,607	$ 1,201,332	$ (3,694,588)
Proceeds from a private placement	$ 12,000,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Inventory (Details) - USD ($)	Mar. 31, 2015	Sep. 30, 2014
Inventory [Abstract]
Raw materials		$ 10,480
Work in process	135,151	24,411
Inventory	$ 135,151	$ 34,891

Property, Plant and Equipment, net (Narrative) (Details) - USD ($)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment, net [Abstract]
Depreciation expense	$ 77,602	$ 64,771

Property, Plant and Equipment, net (Details) - USD ($)	Mar. 31, 2015	Sep. 30, 2014	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 963,586	$ 906,603	$ 893,126
Less: accumulated depreciation	(595,154)	(518,263)	(505,734)
Property, Plant and Equipment, net	368,432	388,340	387,392
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	58,923	58,923	58,923
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	62,033	62,033	62,033
Computer and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	77,678	77,697	77,697
Tools and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	644,965	635,766	622,289
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	10,997	10,997	10,997
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 108,990	$ 61,187	$ 61,187

Intangible Assets - Licensing Rights (Details) - Licensing Rights [Member] - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Aug. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Licence fee for the licensing rights			$ 200,000
Estimated useful life	7 years
Amortization expense		$ 14,286

Commitments (Narrative) (Details) - USD ($)	6 Months Ended		12 Months Ended
Commitments (Narrative) (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014	Aug. 31, 2014	Aug. 31, 2013
Commitments [Abstract]
Rent expense on lease agreements	$ 91,000	$ 90,000
Agreements with contract manufacturing organizations and consultants [Member]
Purchase Obligations [Line items]
Purchase obligations	70,000
Agreements to pay time and materials to contractors [Member]
Purchase Obligations [Line items]
Purchase obligations	85,000
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions	$ 33,000	27,000
Employee vesting percentage	100.00%
Annual non-elective safe harbor employer contribution	3.00%
Licensing Agreements [Member]
Other Commitments [Line Items]
License costs			$ 200,000	$ 25,000
Patent cost reimbursement	$ 30,000	$ 22,000
Common shares issued upon execution of license agreement				371,200
Common shares to be called by warrants				278,400
Aggregate milestone payments upon achievement of financing and development targets	6,020,000
Contingent milestone payments due upon achievement of sales target	$ 57,025,000
Milestone payment			$ 100,000

Commitments (Schedule of Future Minimum Lease Payments) (Details)	Mar. 31, 2015 USD ($)
For The Year Ending September 30,
2015	$ 79,000
2016	59,000
Future minimum lease payments, total	$ 138,000

Share Capital (Schedule of Transactions In Share Capital) (Details) - USD ($)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share Capital [Abstract]
Number of common shares issued	126,800	6,475,820
Proceeds from exercise of warrants and broker units	$ 938	$ 2,587,014
Transfer to common shares on exercise of warrants and broker units	426	5,308,382
Proceeds from exercise of options	27,781	376,148
Transfer to common shares on exercise of options	27,619	341,594
Share-based compensation	$ 198,927	$ 614,312

Share Capital (Schedule of Warrants Activity) (Details)	6 Months Ended
Share Capital (Schedule of Warrants Activity) (Details)	Mar. 31, 2015 $ / shares shares
Share Capital [Abstract]
Number of Warrants, Beginning Balance \| shares	10,545,312
Number of Warrants Exercised \| shares	(600)
Number of Warrants Expired \| shares	(278,700)
Number of Warrants, Ending Balance \| shares	10,266,012
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 1.01
Weighted Average Exercise Price, Exercised \| $ / shares	0.75
Weighted Average Exercise Price, Expired \| $ / shares	1.25
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 1.15

Share Capital (Summary of Outstanding Warrants) (Details)	6 Months Ended
	Mar. 31, 2015 $ / shares shares	Mar. 31, 2015 $ / shares shares	Sep. 30, 2014 $ / shares shares
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares		$ 1.15	$ 1.01
Number of Warrants \| shares	10,266,012	10,266,012	10,545,312
Warrant One [Member]
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares		$ 0.40
Number of Warrants \| shares	4,000,000	4,000,000
Expiry Date	Oct. 25, 2015
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares		$ 0.40
Number of Warrants \| shares	278,400	278,400
Expiry Date	Jan. 04, 2016
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares	$ 1.35
Number of Warrants \| shares	4,701,902	4,701,902
Expiry Date	Sep. 09, 2016
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares	$ 1.35
Number of Warrants \| shares	952,377	952,377
Expiry Date	Sep. 20, 2016
Broker warrants [Member] \| Warrant Four [Member]
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares	$ 1.05
Number of Warrants \| shares	200,000	200,000
Expiry Date	Sep. 09, 2016
Broker warrants [Member] \| Warrant Six [Member]
Class of Warrant or Right [Line Items]
Exercise Price \| $ / shares	$ 1.05
Number of Warrants \| shares	133,333	133,333
Expiry Date	Sep. 20, 2016

Share Capital (Schedule Of Warrants Exercised, Fair Value Assumptions) (Details) - Warrants Exercised [Member]	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Class of Warrant or Right [Line Items]
Risk free interest rate	1.12%	1.07%
Expected life (years)	4 days	3 months 14 days
Expected share price volitility	97.00%	106.00%

Share Capital (Schedule of Broker Units Activity) (Details)	6 Months Ended
	Mar. 31, 2015 $ / shares shares
Share Capital [Abstract]
Number of units, Beginning Balance \| shares	467,200
Number of units, Exercised \| shares	(1,200)
Number of units, Ending Balance \| shares	466,000
Weighted average exercise price, Beginning Balance \| $ / shares	$ 0.25
Weighted average exercise price, Exercised \| $ / shares	0.50
Weighted average exercise price, Ending Balance \| $ / shares	$ 0.25

Share Capital (Summary of Outstanding Broker Units) (Details) - $ / shares	6 Months Ended
	Mar. 31, 2015	Sep. 30, 2014
Class of Warrant or Right [Line Items]
Number of Units	466,000	467,200
Broker Unit One [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.25
Number of Units	400,000
Expiry Date	Oct. 25, 2015
Broker Unit Two [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.25
Number of Units	66,000
Expiry Date	Jan. 04, 2016

Share Capital (Schedule of Stock Option Activity) (Details)	6 Months Ended
	Mar. 31, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance \| shares	5,885,533
Number of Options, Granted \| shares	102,500
Number of Options, Exercised \| shares	(125,000)
Number of Options, Ending Balance \| shares	5,863,033
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 0.62
Weighted Average Exercise Price, Granted \| $ / shares	1.52
Weighted Average Exercise Price, Exercised \| $ / shares	0.25
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 0.67

Share Capital (Summary of Stock Options Outstanding and Exercisable) (Details)	6 Months Ended
	Mar. 31, 2015 $ / shares shares	Mar. 31, 2015 $ / shares shares	Sep. 30, 2014 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	5,863,033	5,863,033	5,885,533
Exercisable at December 31, 2014	5,499,701	5,499,701
2013 Fixed Stock Option Plan [Member] \| Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.28
Number of Options	1,645,000	1,645,000
Exercisable at December 31, 2014	1,645,000	1,645,000
Expiry Date	Apr. 09, 2017
2013 Fixed Stock Option Plan [Member] \| Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.25
Number of Options	55,000	55,000
Exercisable at December 31, 2014	55,000	55,000
Expiry Date	May 17, 2017
2013 Fixed Stock Option Plan [Member] \| Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.28
Number of Options	20,000	20,000
Exercisable at December 31, 2014	20,000	20,000
Expiry Date	Jun. 28, 2017
2013 Fixed Stock Option Plan [Member] \| Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.28
Number of Options	70,000	70,000
Exercisable at December 31, 2014	70,000	70,000
Expiry Date	Jul. 13, 2017
2013 Fixed Stock Option Plan [Member] \| Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.64
Number of Options	70,000	70,000
Exercisable at December 31, 2014	70,000	70,000
Expiry Date	Oct. 25, 2017
2013 Fixed Stock Option Plan [Member] \| Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 1.00
Number of Options	60,000	60,000
Exercisable at December 31, 2014	60,000	60,000
Expiry Date	Feb. 10, 2018
2013 Fixed Stock Option Plan [Member] \| Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.65
Number of Options	848,600	848,600
Exercisable at December 31, 2014	848,600	848,600
Expiry Date	Aug. 08, 2018
2013 Fixed Stock Option Plan [Member] \| Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.50
Number of Options	5,000	5,000
Exercisable at December 31, 2014	5,000	5,000
Expiry Date	Sep. 26, 2018
2013 Fixed Stock Option Plan [Member] \| Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 1.87
Number of Options	100,000	100,000
Exercisable at December 31, 2014	66,667	66,667
Expiry Date	Nov. 07, 2018
2013 Fixed Stock Option Plan [Member] \| Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.40
Number of Options	70,000	70,000
Exercisable at December 31, 2014	70,000	70,000
Expiry Date	Dec. 22, 2018
2013 Fixed Stock Option Plan [Member] \| Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.42
Number of Options	853,600	853,600
Exercisable at December 31, 2014	853,600	853,600
Expiry Date	Apr. 13, 2019
2013 Fixed Stock Option Plan [Member] \| Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.29
Number of Options	90,000	90,000
Exercisable at December 31, 2014	90,000	90,000
Expiry Date	Jun. 18, 2019
2013 Fixed Stock Option Plan [Member] \| Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.37
Number of Options	150,000	150,000
Exercisable at December 31, 2014	150,000	150,000
Expiry Date	Aug. 09, 2019
2013 Fixed Stock Option Plan [Member] \| Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.37
Number of Options	150,000	150,000
Exercisable at December 31, 2014	150,000	150,000
Expiry Date	Aug. 16, 2019
2013 Fixed Stock Option Plan [Member] \| Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.25
Number of Options	8,333	8,333
Exercisable at December 31, 2014	8,333	8,333
Expiry Date	Oct. 23, 2019
2013 Fixed Stock Option Plan [Member] \| Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.25
Number of Options	215,000	215,000
Exercisable at December 31, 2014	215,000	215,000
Expiry Date	Dec. 19, 2019
2013 Fixed Stock Option Plan [Member] \| Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.58
Number of Options	560,000	560,000
Exercisable at December 31, 2014	560,000	560,000
Expiry Date	May 14, 2020
2013 Fixed Stock Option Plan [Member] \| Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.58
Number of Options	100,000	100,000
Exercisable at December 31, 2014	100,000	100,000
Expiry Date	May 23, 2020
2013 Fixed Stock Option Plan [Member] \| Stock Option Ninteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 1.83
Number of Options	495,000	495,000
Exercisable at December 31, 2014	330,000	330,000
Expiry Date	Nov. 01, 2020
2013 Fixed Stock Option Plan [Member] \| Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 1.84
Number of Options	100,000	100,000
Exercisable at December 31, 2014	66,667	66,667
Expiry Date	Nov. 15, 2020
2013 Fixed Stock Option Plan [Member] \| Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 0.94
Number of Options	95,000	95,000
Exercisable at December 31, 2014	31,667	31,667
Expiry Date	Jun. 27, 2021
2013 Fixed Stock Option Plan [Member] \| Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares		$ 1.52
Number of Options	102,500	102,500
Exercisable at December 31, 2014	34,167	34,167
Expiry Date	Nov. 12, 2021

Share Capital (Schedule of Stock Options Granted, Fair Value Assumptions) (Details) - Employee Stock Option [Member]	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.71%	1.98%
Expected life (years)	7 years	6 years 8 months 16 days
Expected share price volitility	116.00%	120.00%
Expected dividend yield	0.00%	0.00%

Share Capital (Narrative) (Details)	6 Months Ended
Share Capital (Narrative) (Details)	Mar. 31, 2015 CAD ($) $ / shares	Mar. 31, 2014 CAD ($) $ / shares	Mar. 31, 2015 USD ($) shares	Aug. 31, 2012 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual life remaining on the outstanding options	3 years 8 months 12 days
Weighted average fair value of stock options awarded \| $ / shares	$ 1.34	$ 1.51
Unrecognized share-based compensation expense \| $			$ 80,000
Unrecognized share-based compensation expense, recognition period	1 year 3 months
Intrinsic value of the options exercised \| $	$ 1.15	$ 1.32
Intrinsic value of the vested options \| $			$ 0.63
Broker units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units	7 months 6 days
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual life remaining on the outstanding warrants or broker units	1 year 1 month 2 days
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shared reserved for issuance \| shares				10,000,000
Share based compensation, shares outstanding \| shares			3,838,383
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, shared reserved for issuance \| shares			10,000,000
Share based compensation, stock option vesting schedule	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"><font style="color: black;">The exercise price of an option is set at the closing price of the Company's common shares on the date of grant. Stock options granted to directors, officers, employees and consultants are subject to the following vesting schedule: </font>(a) One-third of the shares subject to the option <font style="color: black;">shall vest immediately; </font>(b) One-third of the shares subject to the option shall vest 12 months from the date of grant; and<font style="color: black;"> </font>(c) One-third of the shares subject to the option shall vest 18 months from the date of grant. Stock options granted to investor relations consultants vest over a period of not less than 12 months with 25% of the shares subject to the option vesting on the date that is three months from the date of grant, and a further 25% vesting on each successive date that is three months from the date of the prior vesting.</div>

Related Party Disclosures (Details) - USD ($)	6 Months Ended
Related Party Disclosures (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014	Aug. 14, 2002
Director and Officer [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Royalty percentage of gross receipts over base amount			5.00%
Gross receipt base amount for royalty calculation			$ 500,000
Royalty expense
A Taiwan Biopharmaceuticals Manufacturer and a Beneficial Owner [Member] \| Collaborative Agreement [Member]
Related Party Transaction [Line Items]
Ownership percentage		5.00%

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Cash Flow Information) (Details) - USD ($)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Cash paid during the period for taxes	$ 18,800	$ 12,200

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Schedule of Supplemental Disclosure of Non-cash Financing and Investing Activities) (Details) - USD ($)	6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]
Transfer to common shares on exercise of warrants and broker units	$ 426	$ 5,308,382
Transfer to common shares on exercise of options	27,619	341,594
Shares subscribed transferred to common stock		$ 77,736

Concentrations of Credit Risk (Details) - Customer Concentration Risk [Member]	1 Months Ended	6 Months Ended		12 Months Ended
	Sep. 30, 2014	Mar. 31, 2015	Mar. 31, 2014	Aug. 31, 2014
Accounts Receivable [Member] \| One Customer [Member]
Concentration Risk [Line Items]
Concentration risk percentage		43.00%		76.00%
Accounts Receivable [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	81.00%
Product Sales and Contract Services Revenue [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage		82.00%	77.00%